LENZ Therapeutics

LENZ Therapeutics is a late-stage clinical company dedicated to developing innovative ophthalmic drug products that improve vision. The company’s lead program is an aceclidine-based eye drop designed to restore near vision loss associated with presbyopia. Globally, presbyopia affects nearly 2 billion people, while in the United States, more than 120 million people are impacted by presbyopia.